Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State

Abstract

Background: Early diagnosis recurrent prostate cancer is a cornerstone for further adequate therapy planning. Therefore, clinical practice and research still focuses on diagnostic tools that can detect prostate cancer in early recurrence when it is undetectable in conventional diagnostic imaging. 18F-PSMA-1007 PET/CT is a novel method to evaluate patients with biochemical recurrent PCa. The aim of this review was to evaluate the role of 18F-PSMA-1007 PET/CT in prostate cancer local recurrence, lymph node metastases and bone metastases detection. Methods: Original studies, reviews and five meta-analyses were included in this article. A total of 70 studies were retrieved, 31 were included in the study. Results: All patients described in the studies underwent 18F-PSMA-1007 PET/CT. The administered 18F-PSMA-1007 individual dose ranged from 159 ± 31 MBq to 363.93 ± 69.40 MBq. Results showed that 18F-PSMA-1007 PET/CT demonstrates a good detection rate in recurrent prostate cancer. Conclusions: 18F-PSMA-1007 PET/CT appears to achieve reliable performance in detecting recurrent prostate cancer. The high detection rate of 18F-PSMA-1007 PET/CT in recurrent prostate cancer was confirmed, especially in local recurrence and small lymph nodes with non-specific characteristics on conventional diagnostic imaging methods. However, several authors emphasize some limitations for this tracer—for example, non-specific uptake in bone lesions that can mimic bone metastases.

Kinetic modeling and parametric imaging of 18F‐PSMA‐11: An evaluation based on total‐body dynamic positron emission tomography scans

“…Different PSMA radiotracers have been reported to present distinctive pharmacokinetic patterns, which might result in different parametric imaging.For instance, although PSMA-11 showed faster intratumoral uptake than PSMA-617 and PSMA-1007, studies using these 68 Ga/ 18 F labeled PSMA-targeted tracers still adopted a mean time interval between tracer injection and imaging acquisition between 50 and 120 min. 1,[29][30][31] Recently, Liu et al suggested that 68 Ga-PSMA-11 PET scanned 35-59 min p.i. showed a similar tumor uptake but lower urinary bladder activity interference.…”

Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens

“…Additional investigation with large cohorts must be conducted to demonstrate if [ 18 F]PSMA-1007 can be used as a theranostics pair for PSMA-617 instead of [ 68 Ga]Ga-PSMA-11 in the future [85,87,90,92]. Despite having several advantages over [ 68 Ga]Ga-PSMA-11, [ 18 F]PSMA-1007 also has a major drawback as occasional unspecific bone uptake [57,93].…”

Management of Advanced Prostate Cancer in the Precision Oncology Era

“…Historically, PET has relied heavily on several generalized radiotracers that exploit the increased metabolic activity of tumors. A radiolabeled glucose derivative, (18)F-2-deoxy-2-fluoro-D: -glucose (FDG)( 18 F-FDG), is a common radiotracer used for many malignancies; however, it lacks sensitivity and specificity for PC [84].…”